- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06422936
Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC) (SPOTLIGHT204)
SPOTLIGHT 204: A Multicenter, Phase 2b, Open-label, Non-randomized, Clinical Trial to Evaluate Safety, Tolerability and Preliminary Efficacy of Intra-lesional BO-112 in Patients With Resectable Primary Low and High Risk Basal Cell Carcinoma
This is a multicenter, phase 2b, open-label, non-randomized, clinical trial to evaluate safety, tolerability, pharmacodynamics and preliminary efficacy of intra-lesional BO-112 in patients with resectable primary low and high risk basal cell carcinoma.
- primary endpoint is complete visual and pathological response [at surgery] on patient level assessed by central review
secondary endpoints are
- Occurrence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to discontinuation or death on patient level.
- Pathological response [at surgery] on patient level assessed by the investigator and central review, respectively, and visual response [during the study and at surgery] on patient level assessed by the investigator and central review, respectively.
- Recurrence [at 12 and 24 months] after surgery on patient level assessed by the investigator.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Marisol Quintero, PhD
- Phone Number: +34 682 544 814
- Email: mquintero@highlighttherapeutics.com
Study Contact Backup
- Name: Zuzana Jirakova Trnkova, MD, PhD
- Phone Number: +34 682 544 814
- Email: zjirakova@highlighttherapeutics.com
Study Locations
-
-
-
Be'er Sheva, Israel
- Recruiting
- Soroka Medical Center
-
Contact:
- Adi Saadia, MD
-
Haifa, Israel
- Not yet recruiting
- Rambam Medical Center
-
Contact:
- Michal Ramon, MD
-
Jerusalem, Israel
- Not yet recruiting
- Hadassah Ein Kerem Medical Center
-
Contact:
- Sharon Merims, MD
-
Tel Aviv, Israel
- Not yet recruiting
- Sourasky Medical Center
-
Contact:
- Gila Isman-Nelkenbaum, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Participant must be ≥ 18 years old [or the legal age of consent in the jurisdiction in which the study is taking place], at the time of signing the informed consent.
Type of Participant and Disease Condition
- Has primary resectable low or high risk basal cell carcinoma according to the protocol definition
- Has diagnostic punch biopsy of all lesions intended for injection available prior to the first dose of BO-112.
- Has adequate organ function defined as defined per protocol
- Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of study drug.
- Women of childbearing potential must be willing to use two effective methods of birth control while treated with BO-112 and for 4 weeks after the last treatment. The two forms of birth control authorized are defined as the use of a barrier method of contraception (condom with spermicide) in association with one of the following methods of birth control: bilateral tubal ligation; combined oral contraceptives (estrogens and progesterone) or implanted or injectable contraceptives from the time of informed consent.
Male patients with female partners of childbearing potential must be willing to use two adequate contraception methods while treated with BO-112 and for 4 weeks after treatment completion.
Informed Consent
- Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- Able and willing to comply with all study requirements, including surgical removal of lesion/lesion site at completion of study.
Exclusion Criteria:
1. Has history of hypersensitivity to BO-112 or its excipients/vehicle. 2. Has any BCC lesion(s) in site of prior radiation and/or any BCC lesion(s) within 2 cm of the open eyelid margins 4. Has Gorlin's syndrome 5. Has clinically active or uncontrolled skin disease or tattoos that would interfere with evaluation of the area surrounding the target lesion 6. Has another malignant disease requiring treatment 7. Has a history of immunological disorder, severe allergic reaction, moderate or severe asthma or known history of anaphylaxis or any other serious adverse reactions to the investigational products.
8. Female participants: lactating or pregnant. 9. Has received a live vaccine or messenger ribonucleic acid (mRNA) Corona virus disease (COVID) vaccine within 7 days prior to the first dose of study drug or has a vaccination planned during treatment with BO-112 and within 7 days after the last study drug administration.
10. Is immunocompromised. Systemic corticosteroids at >10 mg/day prednisone or equivalent within 1 week prior to the first dose of BO-112.
11. Has any prior systemic anti-lesion therapy or local treatment for study lesions prior to first dose; any chemotherapy or immunotherapy for any other malignancy within 24 months prior to the first dose of BO-112.
12. Has any experimental or investigational agents within one month of first BO-112 injection.
13. Has received or is expected to receive treatment with psoralen plus ultraviolet A (UVA) or ultraviolet B (UVB) therapy within 6 months prior to the first dose of BO-112.
14. Requires / or has used topical products within 5 cm of a treatment-targeted BCC lesion or systemic therapies that might interfere with the evaluation of the study medication during the study.
15. Has any other concurrent anti-cancer therapy (chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational [used for a not approved indication and in the context of a research investigation]) within 28 days of first study drug administration; or plans to participate in an experimental drug study while enrolled in this study.
16. Has any medical contraindications to surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort I
patients with low risk nodular BCC
|
Noncoding double-stranded (ds) RNA based on polyinosinic-polycytidylic acid (Poly I:C), formulated with polyethylenimine (PEI) for intra-lesional injection
|
Experimental: Cohort II
patients with high risk BCC
|
Noncoding double-stranded (ds) RNA based on polyinosinic-polycytidylic acid (Poly I:C), formulated with polyethylenimine (PEI) for intra-lesional injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Complete Visual and Pathological Response
Time Frame: at 24 weeks
|
Complete visual and pathological response of all treated BCC lesions on participant level assessed by central review
|
at 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of Visual Lesion Appearance
Time Frame: at baseline and at 24 weeks
|
Visual response [during the study and at surgery] on participant level assessed by the investigator and central review, respectively.
|
at baseline and at 24 weeks
|
Number of Participants with BCC Recurrence
Time Frame: at 12 and 24 months after surgery
|
Recurrence after surgery on participant level assessed by the investigator
|
at 12 and 24 months after surgery
|
Number of Participants with Treatment-Related Adverse Events assessed by CTCAE 5.0
Time Frame: through study completion, average 7 months
|
Occurrence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to discontinuation or death on participant level.
|
through study completion, average 7 months
|
Extent of Pathological Response
Time Frame: at 24 weeks
|
Pathological response on participant level assessed by the investigator and central review, respectively, using a 4-point scale
|
at 24 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BOT-112-204
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Basal Cell Carcinoma
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell Carcinoma | BCC | BCC - Basal Cell Carcinoma | Basal Cell CancerUnited States
-
Christopher ZacharyRecruitingBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
MediWound LtdRecruitingNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
University of MiamiCompletedNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
University Hospital, BordeauxCompletedLocally Advanced Basal Cell Carcinoma | Metastatic Basal Cell CarcinomaFrance
-
Graceway Pharmaceuticals, LLCCompletedSuperficial Basal Cell CarcinomaAustralia, New Zealand
-
Seton Healthcare FamilyUniversity of Texas at Austin; Dell Medical School at The University of Texas...WithdrawnBasal Cell Carcinoma (BCC) | Squamous Cell Carcinoma (SCC)
-
Biofrontera Bioscience GmbHAccovion GmbHCompletedBasal Cell Carcinoma (BCC)Germany
-
Berg, LLCCompletedSuperficial Basal Cell CarcinomaUnited States
-
PeplinCompletedSuperficial Basal Cell CarcinomaAustralia
Clinical Trials on BO-112
-
Jonsson Comprehensive Cancer CenterMerck Sharp & Dohme LLC; Highlight TherapeuticsTerminatedAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Refractory Hepatocellular CarcinomaUnited States
-
Highlight TherapeuticsPivotal S.L.Completed
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Highlight TherapeuticsActive, not recruitingLeiomyosarcoma | Malignant Peripheral Nerve Sheath Tumor | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Undifferentiated High Grade Pleomorphic Sarcoma of Bone | Myxofibrosarcoma | Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage III Soft Tissue Sarcoma of the... and other conditionsUnited States
-
Clinica Universidad de Navarra, Universidad de...Highlight TherapeuticsRecruitingNon-Small Cell Lung Cancer MetastaticSpain
-
Highlight TherapeuticsTerminatedGastric Cancer | Colorectal Cancer | Oesophageal CancerSpain, Belgium, Italy
-
Highlight TherapeuticsMerck Sharp & Dohme LLCActive, not recruiting
-
Chugai Pharma USACompletedAtherosclerosis | Coronary Restenosis | Graft Occlusion, VascularUnited States
-
Federal University of São PauloUnknown
-
Promontory Therapeutics Inc.Active, not recruitingUrogenital Neoplasms | Neoplasms by Site | Genital Neoplasms, Male | Prostatic Neoplasms | Advanced Solid Tumors | mCRPC | Metastatic Castrate-resistant Prostate Cancer | CRPC | PT-112United States, France
-
Promontory Therapeutics Inc.CompletedMultiple MyelomaUnited States